130.40
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $130.40, with a volume of 5.95M.
It is down -2.42% in the last 24 hours and down -5.58% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$133.64
Open:
$131.54
24h Volume:
5.95M
Relative Volume:
0.88
Market Cap:
$161.85B
Revenue:
$29.45B
Net Income/Loss:
$8.51B
P/E Ratio:
19.23
EPS:
6.7823
Net Cash Flow:
$9.46B
1W Performance:
-5.26%
1M Performance:
-5.58%
6M Performance:
+7.82%
1Y Performance:
+22.85%
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences Inc
|
130.40 | 161.85B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
|
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Vanguard Group Inc. Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Concurrent Investment Advisors LLC Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Axecap Investments LLC Has $3.43 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
AEGON ASSET MANAGEMENT UK Plc Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Impax Asset Management Group plc Acquires 19,894 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Polaris Capital Management LLC - MarketBeat
Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability - ChartMill
Calamos Advisors LLC Sells 9,121 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance Australia
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD - Yahoo Finance
NBC Securities Inc. Acquires 10,296 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD is Kerusso Capital Management LLC's 6th Largest Position - MarketBeat
Teacher Retirement System of Texas Sells 33,061 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Boosted by China Universal Asset Management Co. Ltd. - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Arizona State Retirement System - MarketBeat
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Transforming What’s Next, Now: Gilead’s 2025 Responsible Business and Impact Report - Gilead Sciences
Gilead Sciences (GILD) Ends Losing Streak with 0.56% Gain - GuruFocus
Gilead Sciences nears $2B deal for Ouro MedicinesFT - MSN
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Benzinga
Milestone Asset Management LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences: Core HIV and Liver Franchises Drive EPS Upside and Support Buy Rating Despite Cell Therapy Headwinds - TipRanks
GILD (Gilead Sciences Inc.) reports narrow Q4 2025 earnings beat and mild revenue growth, shares dip slightly.Mature Phase - Xã Thanh Hà
Gilead Sciences, Inc. $GILD Holdings Decreased by Ruffer LLP - MarketBeat
Caprock Group LLC Buys 12,895 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
B. Metzler seel. Sohn & Co. AG Acquires 17,584 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc. (GILD) Announces Q1 2026 Earnings Release Date, Signaling Near-Term Upside CatalystSurprise Factor - Xã Thanh Hà
FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral - MedCity News
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Business Wire
Gilead Sciences stock price forecast: limited upside as GILD trades near support after weekly decline - Traders Union
Gilead set to report as Yeztugo launch, M&A strategy face test - Investing.com
Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Merck steps up as ‘meaningful competitor’ to Gilead with HIV pill approval - BioSpace
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance
Release of 2025 impact report weighs on Gilead Sciences stock amid oversold momentum signals - Traders Union
Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026? - TIKR.com
7,568 Shares in Gilead Sciences, Inc. $GILD Acquired by Ticino Wealth - MarketBeat
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls - BioSpace
Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions - marketscreener.com
Arcus pulls another TIGIT trial as Gilead steps back - The Pharma Letter
Zacks Research Predicts Lower Earnings for Gilead Sciences - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: A Healthcare Giant with a 15% Upside Potential - DirectorsTalk Interviews
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance
Lobbying Update: $3,190,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 EarningsBut Won't (NASDAQ:GILD) - Seeking Alpha
Leerink cuts Arcus Biosciences stock price target on Gilead collaboration end - Investing.com Canada
Gilead Sciences stock edges lower as company discusses expanding oncology reach at AACR26 - Traders Union
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Apr 15 '26 |
Sale |
140.96 |
3,000 |
422,880 |
128,779 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):